

Wholesale Acquisition Cost Information for Vermont Prescribers

KRAZATI® (adagrasib)

Vermont law requires prescription drug manufacturers to disclose in writing to Vermont prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the product listed below.

NDC	MIRATI PRODUCT	DOSAGE FORM	STRENGTH	UNIT SIZE	WAC*
80739-812-18	KRAZATI (adagrasib)	Tablets	200 mg tablets	Carton contains 180 tablets for a 30-day supply.	\$22,149.25

The price paid by patients to acquire the product listed is often different than the WAC price listed, and most patients do not pay WAC. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company or preferred pharmacy.

Vermont law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” There are no generic prescription drugs that are in the same “therapeutic class” (based on the definition of “therapeutic class” under Vermont law) as KRAZATI. There are also no generic prescription drugs for KRAZATI.

*Pricing as of Q1 2024. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates, or reduction in price.

